Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with gleason score 8 to 10 prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 1949-1956

  Pahlajani, Niraj ^a   Ruth, Karen J ^b   Buyyounouski, Mark K ^b   Chen, David Y T ^b   Horwitz, Eric M ^b   Hanks, Gerald E ^b   Price, Robert A ^b   Pollack, Alan ^c  

^a Department of Anesthesiology   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dose escalation; High grade; Radiation; Survival

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BIOCHEMICAL FAILURE; COMPETING RISKS; CONTINUOUS VARIABLES; COX REGRESSION ANALYSIS; DISTANT METASTASIS; DOSE ESCALATION; GLEASON SCORES; HIGH GRADE; LOCAL FAILURE; MICROMETASTATIC DISEASE; PROSTATE CANCERS; SIMILAR MODELS; SURVIVAL;

DISEASES; HEAT RADIATION; RADIOTHERAPY; REGRESSION ANALYSIS; STATISTICS;

RISK PERCEPTION;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; REGRESSION ANALYSIS; SEMINAL VESICLES; SURVIVAL ANALYSIS;

EID: 84858698777     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.04.005     Document Type: Article

References (34)

1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
2. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233-1239. (Pubitemid 41352111)
3. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized Phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24: 1990-1996. (Pubitemid 46622106)
4. DearnaleyDP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-487. (Pubitemid 46805903)
5. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-2504.
6. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-2527.
7. American Joint Commission on Staging of Cancer. Manual for Staging of Cancer. 4 ed. Philadelphia: JB Lippincott; 1992.
8. Soffen EM, Hanks GE, Hunt MA, et al. Conformal static field radiation therapy treatment of early prostate cancer versus nonconformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992;24:485-488.
9. Horwitz EM, Hanlon AL, Pinover WH, et al. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques. Cancer 2001;92:1281-1287.
10. Monti AF, Ostinelli A, Frigerio M, et al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol 1995;35:145-150.
11. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-526. (Pubitemid 43083441)
12. Das IJ, ChengCW, Chopra KL, et al. Intensity-modulated radiation therapy dose prescription, recording, and delivery: Patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst 2008;100:300-307. (Pubitemid 351480524)
13. Senthi S, Gill SS, Haworth A, et al. Benchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:998-1005.
14. Kukolowicz PF, Mijnheer BJ. Comparison between dose values specified at the ICRU reference point and the mean dose to the planning target volume. Radiother Oncol 1997;42:271-277. (Pubitemid 27179681)
15. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-526. (Pubitemid 43083441)
16. Roach M 3rd, Hanks G, Thames H Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
17. Buyyounouski MK, Hanlon AL, Eisenberg DF, et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2005;63:1455-1462. (Pubitemid 41628042)
18. Eade TN, Horwitz EM, Ruth K, et al.Acomparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008;71:338-345.
19. Intensity-modulated radiotherapy: Current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880-914.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:447-457.
21. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988;16: 1141-1143.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999;94: 496-509.
23. Cox DR, Oakes D. Proportional Hazards Model. In: Analysis of Survival Data. London: Chapman and Hall; 1984.
24. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical computing; 2007.
25. Fiveash JB, Hanks G, Roach M, et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi- institutional review. Int J Radiat Oncol Biol Phys 2000;47: 335-342. (Pubitemid 30236373)
26. Roach M, Meehan S, Kroll S. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996; 156:1719-1723. (Pubitemid 26344026)
27. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028-1033.
28. Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002;54:677-685.
29. Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008; 179:1368-1373. discussion 1373.
30. Crook JM, Malone S, Perry G, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial. Cancer 2009;115:673-679.
31. Schulz RJ, Kagan AR. Commentary on dose escalation and biochemical failure in prostate cancer: in regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68:682-689). Int J Radiat Oncol Biol Phys 2008;70:645; author reply 645-646.
32. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70: 1124-1129. (Pubitemid 351296130)
33. Chism DB, Hanlon AL, Troncoso P, et al. The Gleason score shift: Score four and seven years ago. Int J Radiat Oncol Biol Phys 2003;56:1241-1247. (Pubitemid 36842874)
34. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A Phase III randomised trial. Lancet 2002;360: 103-106.